RIPK1 Inhibitor Compounds for Targeted Inflammation Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Chronic inflammation and dysregulation of receptor-interacting protein kinase 1 signaling lead to various human diseases, including neurodegenerative disorders and autoimmune conditions, highlighting the need for effective inhibitors to modulate inflammatory responses and cell death pathways.
Innovation Solution
Development of compounds that act as inhibitors of receptor-interacting protein kinase 1, formulated into pharmaceutical compositions for treating diseases mediated by this kinase, such as inflammatory bowel disease and neurodegenerative disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If receptor-interacting protein kinase 1 signaling is left unregulated, then normal cellular functions are maintained, but chronic inflammation and cell death pathways are activated leading to diseases
Solution Approach 1:
The patent employs small molecule compounds as intermediaries to modulate receptor-interacting protein kinase 1 activity. These compounds act as mediators between the kinase and its substrates, preventing excessive signaling that leads to chronic inflammation and cell death, thereby treating autoimmune and inflammatory diseases without completely blocking normal cellular functions
2Object-generated harmful factors
If receptor-interacting protein kinase 1 activity is completely inhibited, then inflammatory responses are suppressed, but normal immune function and cell death regulation are compromised
Solution Approach 1:
The patent utilizes compounds that modulate receptor-interacting protein kinase 1 activity by changing kinetic parameters rather than complete inhibition. The compounds alter the enzyme-substrate interaction dynamics, reducing excessive phosphorylation events that drive inflammation while preserving baseline kinase activity necessary for normal immune function and controlled cell death
3Reliability
If high doses of kinase inhibitors are used, then therapeutic efficacy is improved, but off-target effects and toxicity increase
Solution Approach 1:
The patent employs compounds with highly specific molecular structures designed to interact with unique features of receptor-interacting protein kinase 1's active site. This local specificity ensures that the inhibitors bind selectively to the target kinase without affecting other kinases or cellular components, achieving high therapeutic efficacy at lower doses with minimal off-target effects
Data Source
AI summary
The present disclosure relates generally to compounds and compositions, and their use as kinase inhibitors.